Camp4 Therapeutics (CAMP) Non-Current Deffered Revenue (2025 - 2026)
Camp4 Therapeutics recorded quarterly Non-Current Deffered Revenue of $5.2 million in Q1 2026, down 35.72% quarter-over-quarter from $8.1 million in Q4 2025.
Camp4 Therapeutics' Non-Current Deffered Revenue history runs 2 years deep, the most recent figure standing at $5.2 million for Q1 2026.
- In Q1 2026, Non-Current Deffered Revenue changed N/A year-over-year to $5.2 million; the TTM figure through Mar 2026 stood at $5.2 million (changed N/A YoY), while the FY2025 annual figure was $8.1 million, changed N/A from the prior year.
- Non-Current Deffered Revenue came in at $5.2 million for Q1 2026 at Camp4 Therapeutics, down from $8.1 million in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $8.1 million in Q4 2025 to a low of $5.2 million in Q1 2026.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 225.10 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Camp4 Therapeutics | 245.89 Mn | 245.89 Mn | - | 5.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.22 Mn |
| Dec 31, 2025 | 8.11 Mn |